Neurológia pre prax 1/2018
Anti CD20 multiple sclerosis therapy
The efficacy of multiple sclerosis therapy by monoclonal anti- CD 20 antibodies was confirmed in clinical trials. Three monoclonal antibodies ocrelizumab, rituximab and ofatumumab are effective. The efficacy of ocrelizumab was shown in relaps-remitting and primary progressive course of multiple sclerosis and broadens the spectrum of multiple sclerosis therapy. In primary progressive course of multiple sclerosis ocrelizumab is the only effective therapy until now.
Keywords: CD 20, B-cells, ocrelizumab, rituximab, ofatumumab
